PMID- 36116416
OWN - NLM
STAT- MEDLINE
DCOM- 20221012
LR  - 20240102
IS  - 1879-3320 (Electronic)
IS  - 0960-7404 (Linking)
VI  - 44
DP  - 2022 Sep
TI  - Role of genetic testing in hepatic, pancreatic, and biliary cancers.
PG  - 101844
LID - S0960-7404(22)00139-6 [pii]
LID - 10.1016/j.suronc.2022.101844 [doi]
AB  - Hepatic, pancreatic, and biliary (HPB) cancers, including hepatocellular 
      carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), and cholangiocarcinoma 
      (CCA) cause a disproportionate amount of the global cancer-related mortality. 
      Despite advances in surgical technique and improved systemic therapies, overall 
      5-year survival remains dismal, especially for patients with pancreatic and 
      biliary cancer. Historically, systemic therapies for patients with HPB cancers 
      were administered in a "one-size-fits-all" approach due to limited reliable data 
      on efficacy for specific patient populations. However, recent advances in genetic 
      testing techniques have greatly improved our understanding of HPB oncogenesis, 
      shedding light on specific genetic mutations responsible for progression from 
      physiologic cellular regulation to uninhibited cellular replication and invasive 
      cancer. Investigations into the oncogenesis of HPB cancers have revealed multiple 
      actionable genetic variants, as well as increased susceptibilities to currently 
      available systemic therapies. For example, patients with PDAC and a known BRCA 
      mutation are more likely to benefit from FOLFIRINOX or gemcitabine plus 
      cisplatin. While patients with CCA and a IDH1 mutation may benefit from 
      ivosidenib. As a result, many national and societal guidelines now recommend some 
      form of genetic testing in the workup of patients with HPB cancers. We herein 
      review the role of genetic testing in these aggressive cancers including DNA 
      sequencing techniques, clinically relevant mutations, therapeutic implications, 
      and current clinical recommendations.
CI  - Copyright (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Hewitt, D Brock
AU  - Hewitt DB
AD  - Department of Surgery, The Ohio State Wexner Medical Center, Columbus, OH, USA.
FAU - Aziz, Hassan
AU  - Aziz H
AD  - Department of Surgery, Tufts University Medical Center, Boston, MA, USA.
FAU - Brown, Zachary J
AU  - Brown ZJ
AD  - Department of Surgery, The Ohio State Wexner Medical Center, Columbus, OH, USA.
FAU - Pawlik, Timothy M
AU  - Pawlik TM
AD  - Department of Surgery, The Ohio State Wexner Medical Center, Columbus, OH, USA. 
      Electronic address: Tim.pawlik@osumc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220905
PL  - Netherlands
TA  - Surg Oncol
JT  - Surgical oncology
JID - 9208188
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Bile Duct Neoplasms/pathology
MH  - Bile Ducts, Intrahepatic/pathology
MH  - *Biliary Tract Neoplasms/genetics
MH  - Carcinogenesis/genetics
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - *Carcinoma, Pancreatic Ductal/pathology
MH  - Cisplatin/therapeutic use
MH  - Genetic Testing
MH  - Humans
MH  - *Liver Neoplasms/drug therapy/genetics
MH  - *Pancreatic Neoplasms/pathology
OTO - NOTNLM
OT  - Biliary
OT  - Cancer
OT  - Genetics
OT  - Liver
OT  - Pancreas
OT  - Testing
EDAT- 2022/09/19 06:00
MHDA- 2022/10/13 06:00
CRDT- 2022/09/18 18:25
PHST- 2022/06/19 00:00 [received]
PHST- 2022/08/21 00:00 [revised]
PHST- 2022/08/24 00:00 [accepted]
PHST- 2022/09/19 06:00 [pubmed]
PHST- 2022/10/13 06:00 [medline]
PHST- 2022/09/18 18:25 [entrez]
AID - S0960-7404(22)00139-6 [pii]
AID - 10.1016/j.suronc.2022.101844 [doi]
PST - ppublish
SO  - Surg Oncol. 2022 Sep;44:101844. doi: 10.1016/j.suronc.2022.101844. Epub 2022 Sep 
      5.